Ian A. White, MS, Ph.D., Founder, President & Chief Scientific Officer at Neobiosis speaks about the Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury.
Link to Article:
https://www.pubstemcell.com/epub/016010300010EPA121120.htm?fbclid=IwAR3HybxbXXEBRK4FXsfcUc-MBImTiSc1USuIg-J_8f0JLuwKL3O_oWa1qf4
Cardiovascular disorder claims the lives of over 650,000 Americans per year. (1) Those who survive a myocardial infarction are still at risk of dying because the human heart's capacity to heal itself is limited. No one has yet discovered a mechanism for regenerating a weakened human heart's cardiovascular system. But it could all improve due to a groundbreaking medical paper written by Dr. Ian White, President and Chief Scientific Officer of Neobiosis, a regenerative medicine corporation.
A mouse heart, like the hearts of other mammals, has a very brief time (1-7 days) after birth where it maintains its primordial regenerative powers. White's latest approach, however, maintains a neonatal mouse heart alive and beating in a stable environment for up to a month, extending the regenerative cycle. This gives scientists more time to figure out how various treatments or medications can help the weakened organ heal or rebuild.
The epicardium, a single layer of cells that protects the nucleus, is involved in neonatal cardiac recovery, according to White's article. In response to injury, the cells proliferate before successfully migrating to the damaged area.
The discovery has far-reaching health consequences, especially for those who have suffered heart damage as a result of COVID-19 exposure.
White is happy to share his creations with the rest of the world. He also urged colleagues to conduct their own studies using the same neonatal heart preservation process. Neobiosis is a pioneer in the field of regenerative science, as shown by the dissemination of this research.
Regenerative medicine, according to White and his colleagues at the University of Florida's Sid Martin Innovate Biotechnology Institute, carries the promise of long-term survival and wellbeing. Many concerned with the new laboratory are optimistic that their findings and affiliation with the University of Florida would lead to new health therapies, and they also urge the FDA to reconsider its position on this groundbreaking area of science.
Regenerative Therapy's Advantages
Regenerative medicine has the ability to revolutionize healthcare and combat illness. The medications focus on assisting the body in healing, regenerating, and rebuilding itself. These are some of the advantages:
* Using biochemical guidance and raw biomaterials to stimulate the body's own repair processes to functionally restore previously irreparable tissues and organs.
* Reducing inflammation to help with healing and tissue repair.
* Use alternative methods to treat trauma and illness without the use of surgery or opioids.
Cardiac Injury
Description
Cardiac Injury
Marie-Sophie de Koning, MD, PhD Candidate in Cardiology at the UMCG Cardiology Research Institute. In this video, she speaks about AAC 2022 Abstract - Results from the GIPS-IV Trial.
Brief Synopsis:
The most effective treatment for ST-segment elevation myocardial infarction is now timely and successful reperfusion with primary percutaneous coronary intervention (PPCI) (STEMI). However, persistent myocardial injury caused by ischemia and subsequent reperfusion is seen in the vast majority of patients (88%) and poses a risk of heart failure development. In numerous experimental models, hydrogen sulfide (H2S) administration has been found to protect the heart from "ischemia reperfusion injury." Human data suggests that the H2S-releasing chemical sodium thiosulfate (STS) can be safely administered.
The goal of this study was to examine the efficacy and safety of STS versus placebo treatment on myocardial infarct size in STEMI patients treated with PCI.
A multicenter, double-blind, randomized controlled clinical trial was used for the study. A total of 380 patients aged 18 and up who were undergoing primary PCI for a first STEMI and deemed amenable by the investigator to be treated with STS 12.5g intravenously (i.v.) or matched placebo immediately after arrival at the catheterization laboratory (cath-lab) and a repeated dose administered 6 hours after the first dose, on top of standard treatment, were included in the study. The primary endpoint is the size of the infarct as determined by cardiac magnetic resonance imaging (CMR-imaging) four months following randomization.
Marie-Sophie de Koning, MD, PhD Candidate in Cardiology at the UMCG Cardiology Research Institute. In this video, she speaks about AAC 2022 Abstract - Results from the GIPS-IV Trial.
Brief Synopsis:
The most effective treatment for ST-segment elevation myocardial infarction is now timely and successful reperfusion with primary percutaneous coronary intervention (PPCI) (STEMI). However, persistent myocardial injury caused by ischemia and subsequent reperfusion is seen in the vast majority of patients (88%) and poses a risk of heart failure development. In numerous experimental models, hydrogen sulfide (H2S) administration has been found to protect the heart from "ischemia reperfusion injury." Human data suggests that the H2S-releasing chemical sodium thiosulfate (STS) can be safely administered.
The goal of this study was to examine the efficacy and safety of STS versus placebo treatment on myocardial infarct size in STEMI patients treated with PCI.
A multicenter, double-blind, randomized controlled clinical trial was used for the study. A total of 380 patients aged 18 and up who were undergoing primary PCI for a first STEMI and deemed amenable by the investigator to be treated with STS 12.5g intravenously (i.v.) or matched placebo immediately after arrival at the catheterization laboratory (cath-lab) and a repeated dose administered 6 hours after the first dose, on top of standard treatment, were included in the study. The primary endpoint is the size of the infarct as determined by cardiac magnetic resonance imaging (CMR-imaging) four months following randomization.
Ian A. White, MS, Ph.D., Founder, President & Chief Scientific Officer at Neobiosis speaks about the Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury.
Link to Article:
https://www.pubstemcell.com/epub/016010300010EPA121120.htm?fbclid=IwAR3HybxbXXEBRK4FXsfcUc-MBImTiSc1USuIg-J_8f0JLuwKL3O_oWa1qf4
Cardiovascular disorder claims the lives of over 650,000 Americans per year. (1) Those who survive a myocardial infarction are still at risk of dying because the human heart's capacity to heal itself is limited. No one has yet discovered a mechanism for regenerating a weakened human heart's cardiovascular system. But it could all improve due to a groundbreaking medical paper written by Dr. Ian White, President and Chief Scientific Officer of Neobiosis, a regenerative medicine corporation.
A mouse heart, like the hearts of other mammals, has a very brief time (1-7 days) after birth where it maintains its primordial regenerative powers. White's latest approach, however, maintains a neonatal mouse heart alive and beating in a stable environment for up to a month, extending the regenerative cycle. This gives scientists more time to figure out how various treatments or medications can help the weakened organ heal or rebuild.
The epicardium, a single layer of cells that protects the nucleus, is involved in neonatal cardiac recovery, according to White's article. In response to injury, the cells proliferate before successfully migrating to the damaged area.
The discovery has far-reaching health consequences, especially for those who have suffered heart damage as a result of COVID-19 exposure.
White is happy to share his creations with the rest of the world. He also urged colleagues to conduct their own studies using the same neonatal heart preservation process. Neobiosis is a pioneer in the field of regenerative science, as shown by the dissemination of this research.
Regenerative medicine, according to White and his colleagues at the University of Florida's Sid Martin Innovate Biotechnology Institute, carries the promise of long-term survival and wellbeing. Many concerned with the new laboratory are optimistic that their findings and affiliation with the University of Florida would lead to new health therapies, and they also urge the FDA to reconsider its position on this groundbreaking area of science.
Regenerative Therapy's Advantages
Regenerative medicine has the ability to revolutionize healthcare and combat illness. The medications focus on assisting the body in healing, regenerating, and rebuilding itself. These are some of the advantages:
* Using biochemical guidance and raw biomaterials to stimulate the body's own repair processes to functionally restore previously irreparable tissues and organs.
* Reducing inflammation to help with healing and tissue repair.
* Use alternative methods to treat trauma and illness without the use of surgery or opioids.